We showed giving IL-22 increased proliferation of breast cancer cells including estrogen receptor-positive MCF7 cells and triple-negative 4T1 and MDA-MB-231 cells, which indicates IL-22-mediated proliferative effect might not depend on expression of estrogen receptor. This evidence concerns the gene IL22 and breast carcinoma.